This inventor holds 7 USPTO granted patents and 2 published patent applications. Top assignees: The University of British Columbia, Chemokine Therapeutics Corporation, Research Corporation Technologies, Inc.. Active years: 1995-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
5 out of 959 
1 out of 7 
1 out of 366 
Years Active: 1995-2008
Title: Ian Clark-Lewis: Innovator in Therapeutic Chemokine Research
Introduction
Ian Clark-Lewis is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of therapeutic chemokine receptor antagonists, holding a total of seven patents. His work focuses on innovative treatments for various medical conditions, including autoimmune diseases and cancer.
Latest Patents
One of Ian Clark-Lewis's latest patents involves therapeutic chemokine receptor antagonists. This invention provides a variety of therapeutic uses for CXCR4 antagonists. These antagonists can be utilized to reduce interferon gamma production by T-cells, treat autoimmune diseases, address multiple sclerosis, combat cancer, and inhibit angiogenesis. The invention outlines methods of medical treatment where a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Additionally, it includes therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. Another significant patent involves CXC chemokine receptor 4 agonist peptides, which may be used to reduce the rate of hematopoietic cell multiplication. This method includes administering an effective amount of an CXCR4 agonist to hematopoietic stem cells and progenitor cells, either in vitro or in vivo.
Career Highlights
Ian Clark-Lewis has worked with notable institutions, including the University of British Columbia and The Liposome Company, Inc. His research has significantly advanced the understanding of chemokine receptors and their therapeutic applications.
Collaborations
Throughout his career, Ian has collaborated with esteemed colleagues such as Jiang-Hong Gong and Vincent Duronio. These partnerships have contributed to the development of innovative therapeutic strategies.
Conclusion
Ian Clark-Lewis is a distinguished inventor whose work in therapeutic chemokine research has the potential to transform treatment options for various diseases. His contributions continue to impact the medical field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile